AP NEWS

Sterol 14 Alpha-Demethylase Inhibitor Pipeline Insight Report, 2018 Edition - ResearchAndMarkets.com

December 19, 2018

DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Sterol 14 Alpha-Demethylase Inhibitor -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Sterol 14 Alpha-Demethylase Inhibitor - Pipeline Insight, 2018′ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Sterol 14 Alpha-Demethylase Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Gideon Pharmaceuticals Pulmocide Schering-Plough Viamet Pharmaceuticals Daiichi Sankyo Company ProFem Mayne Pharma Basilea Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l5r4pj/sterol_14?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005687/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Enzymes

KEYWORD:

INDUSTRY KEYWORD: MANUFACTURING CHEMICALS/PLASTICS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/19/2018 01:51 PM/DISC: 12/19/2018 01:51 PM

http://www.businesswire.com/news/home/20181219005687/en

AP RADIO
Update hourly